Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-03-08
2011-03-08
Peng, Bo (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S186100, C424S187100, C424S202100, C435S320100, C435S069100
Reexamination Certificate
active
07901690
ABSTRACT:
Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV is disclosed. The composition and methods described herein are for the use of a DNA composition that encodes one or more different HIV envelope glycoproteins. The DNA composition can encode an HIV Gag protein. The DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV protein compositions for inducing an immune response against HIV are disclosed. Methods fro using the protein compositions as boosts following administration of the DNA compositions are provided.
REFERENCES:
patent: 5420030 (1995-05-01), Reitz et al.
patent: 5830876 (1998-11-01), Weiner et al.
patent: 6090392 (2000-07-01), Berman
patent: 6139843 (2000-10-01), Rubinstein et al.
patent: H06-501851 (1994-03-01), None
patent: 2000-516445 (2000-12-01), None
patent: WO 92/22654 (1992-12-01), None
patent: WO 97/48370 (1997-12-01), None
patent: WO 0232943 (2002-04-01), None
patent: 03/039470 (2003-05-01), None
Barnett, S. et al. “Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant GP120 protein subunit” Vaccine vol. 15(1997): pp. 869-873.
Gao F. “Genetic variation of HIV type 1 in four world health organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E” AIDS Res. And Hum Retroviruses, vol. 10 (1994), No. 11, pp. 1359-1368.
Gao F. et al. “Molecular cloning and analysis of functional envelope genes from human immunodeficiecy virus type 1 sequence subtype A through G” J. Virology vol. 70(1996), No. 3, pp. 1651-1667.
Andre S. et al. “Increased immune responses elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage” J. Virology vol. 72(1998), No. 2, pp. 1497-1503.
Pontesilli, O. et al. “Phase II controlled trial of post-exposure immunization with recombinant gp 160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults” AIDS vol. 12 (1998), No. 5, pp. 473-480.
Vandepapelliere p. “Therapeutic vaccination against chronic viral infections” The Lancet Infectious Diseases vol. 2(2002) pp. 353-367.
Yoshida T. et al. “Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols”. Clin Exp Immunol. Jun. 2001;124(3):445-52.
Gao F. et al. “Codon-Usage Optimization of gag, pol, env and nef Genes of an HIV-1 Subtype C Strain”.AIDS Vaccine 2001. Sep. 5-8, 2001; abstract No. 201.
Evans et al. “QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans”. Vaccine. Feb. 28, 2001;19(15-16):2080-91.
Li M, et al. “Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.” J Virol. Aug. 2005;79(16):10108-25.
Mann AM, et al. “HIV sensitivity to neutralization is determined by target and virus producer cell properties.” AIDS.23:1659-1667, 2009.
Desrosiers RC. “Prospects for an AIDS vaccine” Nature Medicine vol. 10 (2004), pp. 221-223.
Fenyo EM et al. “International network for comparison of HIV neutralization assays: the NeutNet report.” PLoS One. 2009;4(2):e4505.
Haynes “Critical issues in mucosal immunity for HIV-1 vaccine development” (J. Allergy Clin Immunol.122:3-9, 2008).
Fomsgaard, A, “HIV-1 DNA Vaccines”Immunology Letters, vol. 65, No. 1/2, pp. 127-131 (1999).
Pal, et al., “Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbints”Vaccine, vol. 24, No. 8, pp. 1225-1234 (2006).
Pal Ranajit, et al., “Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate”Journal of Medical Primatology, vol. 34, No. 5-6, pp. 226-236 (2005).
Weidle, et al., “HIV/AIDS treatment and HIV vaccines for Africa”Lancet, vol. 359, No. 9325, pp. 2261-2267 (2002).
Alonso et al., “Biodegradable microspheres as controlled-release tetanus toxoid delivery systems,” Vaccine 12:299-306 (1994).
Bagarazzi et al., “Nucleic acid-based vaccines as an approach to immunization against human immunodeficiency virus type-1,” Curr. Top Microbiol. Immunol. 226:107-43 (1998).
Barnett et al., “The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region,” J. Virol. 75:5526-40 (2001).
Barouch et al., “Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes,” Nature 415(6869):335-9 (2002).
Boyer et al., “Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination,” Nat. Med. 3(5):526-32 (1997).
Chakrabarti et al., “Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization,” J. Virol. 76(11):5357-68 (2002).
Chapman, et al., “Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells,” Nucleic Acids Res. 19:3979-3986 (1991).
Clements et al., “Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus,” J. Virol. 69: 2737 (1995).
Cristillo et al., “Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine,” Virology 346(1):151-68 (2006).
Eldridge et al., “Biodegradable microspheres as a vaccine delivery system,” Molec. Immunol. 28:287-94 (1991).
Goulder et al., “Evolution and transmission of stable CTL escape mutations in HIV infection,” Nature 412:334-338 (2001).
Goulder et al., “Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS,” Nature Med. 3:212-217 (1997).
Hu et al., “The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses,” Clin. Exp. Immunol. 113:235-43 (1998).
Hurwitz et al., “Application of the polyvalent approach to HIV-1 vaccine development,” Curr. Drug Targets Infect. Disord. 5(2):143-56 (2005).
Johnston and Flores, “Progress in HIV vaccine development,” Curr. Op. In. Pharmac. 1:504-510 (2001).
Jones et al., “Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae,” Vaccine 13(7):675-81 (1995).
Kensil, et al., “QS-21 and QS-7: purified saponin adjuvants,” Dev. Biol. Stand. 92:41-7 (1998).
Kong et al., “Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines,” J. Virol. 77:12764-772 (2003).
Letvin et al., “Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines,” Proc. Natl. Acad. Sci. USA 94(17):9378-83 (1997).
Ljungberg et al., “Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes,” Virology 302(1):44-57 (2002).
Lu et al., “Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/
Kalyanaraman Vaniambadi
Keen Tim
Lu Shan
Markham Phillip
Nair Balachandran
Advanced Bioscience Laboratories
Fish & Richardson P.C.
Peng Bo
University of Massachusetts
LandOfFree
Polyvalent, primary HIV-1 glycoprotein DNA vaccines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyvalent, primary HIV-1 glycoprotein DNA vaccines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyvalent, primary HIV-1 glycoprotein DNA vaccines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2646889